Premium
Ocrelizumab for relapsing or primary progressive MS
Author(s) -
Chaplin Steve
Publication year - 2018
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1705
Subject(s) - ocrelizumab , medicine , multiple sclerosis , relapsing remitting , adverse effect , primary (astronomy) , monoclonal antibody , oncology , immunology , antibody , rituximab , physics , lymphoma , astronomy
Ocrelizumab (Ocrevus) is a new monoclonal antibody treatment for patients with relapsing‐remitting multiple sclerosis (RRMS) and for those with early primary progressive multiple sclerosis (PPMS). This article summarises its indications, efficacy and adverse effects.